Wilkinson, A. C., Igarashi, K. J. & Nakauchi, H. Haematopoietic stem cell self-renewal in vivo and ex vivo. Nat. Rev. Genet. 21, 541–554 (2020).
Google Scholar
Eaves, C. J. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood 125, 2605–2613 (2015).
Google Scholar
Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505, 327–334 (2014).
Google Scholar
Thomas, E. D., Lochte, H. L. Jr., Lu, W. C. & Ferrebee, J. W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 257, 491–496 (1957).
Google Scholar
Wahlstrom, J. T., Dvorak, C. C. & Cowan, M. J. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Curr. Pediatr. Rep. 3, 1–10 (2015).
Google Scholar
Tiercy, J. M. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica 101, 680–687 (2016).
Google Scholar
Granot, N. & Storb, R. History of hematopoietic cell transplantation: challenges and progress. Haematologica 105, 2716–2729 (2020).
Google Scholar
Gragert, L. et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N. Engl. J. Med. 371, 339–348 (2014).
Google Scholar
Hill, G. R., Betts, B. C., Tkachev, V., Kean, L. S. & Blazar, B. R. Current concepts and advances in graft-versus-host disease immunology. Annu. Rev. Immunol. 39, 19–49 (2021).
Google Scholar
Morgan, R. A., Gray, D., Lomova, A. & Kohn, D. B. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell 21, 574–590 (2017).
Google Scholar
Frangoul, H. et al. CRISPR–Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med. 384, 252–260 (2021). This work is the first clinical application of the CRISPR–Cas9 system for ex vivo HSC gene therapy.
Google Scholar
Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N. Engl. J. Med. 378, 1479–1493 (2018). This paper reports clinical trial results from lentiviral-based gene therapy for β-thalassaemia.
Google Scholar
Boztug, K. et al. Stem-cell gene therapy for the Wiskott–Aldrich syndrome. N. Engl. J. Med. 363, 1918–1927 (2010).
Google Scholar
Aiuti, A. et al. Correction of ADA–SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002).
Google Scholar
Czechowicz, A. et al. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat. Commun. 10, 617 (2019).
Google Scholar
Li, C. et al. In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model. Mol. Ther. 29, 822–837 (2021).
Google Scholar
Burns, S. In vivo gene editing of hematopoietic stem and progenitor cells. Intellia https://3o5c4w3neipl16yvhj3nfqam-wpengine.netdna-ssl.com/wp-content/uploads/Keystone_2021_BoneMarrow_10Mar2021-1.pdf (2021). This preclinical data release from Intellia demonstrates in vivo editing of human HSCs in xenografted mice.
Wilkinson, A. C. et al. Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation. Nature 571, 117–121 (2019). This paper is the first to show robust (>100-fold) expansion of HSCs ex vivo.
Google Scholar
Piras, F. & Kajaste-Rudnitski, A. Antiviral immunity and nucleic acid sensing in haematopoietic stem cell gene engineering. Gene Ther. 28, 16–28 (2021).
Google Scholar
Dudek, A. M. & Porteus, M. H. Answered and unanswered questions in early-stage viral vector transduction biology and innate primary cell toxicity for ex-vivo gene editing. Front. Immunol. 12, 660302 (2021).
Google Scholar
Rasaiyaah, J. et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 503, 402–405 (2013).
Google Scholar
Chiu, Y. L. et al. Tat stimulates cotranscriptional capping of HIV mRNA. Mol. Cell 10, 585–597 (2002).
Google Scholar
Piras, F. et al. Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. EMBO Mol. Med. 9, 1198–1211 (2017).
Google Scholar
Wu, X. et al. Intrinsic immunity shapes viral resistance of stem cells. Cell 172, 423–438.e25 (2018).
Google Scholar
Petrillo, C. et al. Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells. Cell Stem Cell 23, 820–832.e9 (2018).
Google Scholar
Vaidyanathan, S. et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol. Ther. Nucleic Acids 12, 530–542 (2018).
Google Scholar
Dowdy, S. F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 35, 222–229 (2017).
Google Scholar
Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).
Google Scholar
Schiroli, G. et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Sci. Transl. Med. 9, eaan0820 (2017).
Google Scholar
Wienert, B., Shin, J., Zelin, E., Pestal, K. & Corn, J. E. In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway. PLoS Biol. 16, e2005840 (2018).
Google Scholar
Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR–Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015). This paper describes the development of chemically modified guides that allow for the first demonstration of CRISPR–Cas9 gene editing in human HSCs.
Google Scholar
Zeng, J. et al. Therapeutic base editing of human hematopoietic stem cells. Nat. Med. 26, 535–541 (2020).
Google Scholar
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019). This paper describes the first demonstration of prime editing, a flexible platform for making gene edits without the use of a double-strand break.
Google Scholar
Liao, W., Du, C. & Wang, J. The cGAS–STING pathway in hematopoiesis and its physiopathological significance. Front. Immunol. 11, 573915 (2020).
Google Scholar
Dever, D. P. et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 539, 384–389 (2016).
Google Scholar
Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235–240 (2014). This work is the first demonstration of gene editing mediated by homology directed repair in HSCs; innate immune signalling of HSCs was overcome using integration-deficient lentiviral vectors.
Google Scholar
Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298–1306 (2007).
Google Scholar
Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551–565.e8 (2019).
Google Scholar
Hosel, M. et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55, 287–297 (2012).
Google Scholar
Zhu, J., Huang, X. & Yang, Y. The TLR9–MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest. 119, 2388–2398 (2009).
Google Scholar
DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).
Google Scholar
Pien, G. C. et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119, 1688–1695 (2009).
Google Scholar
Li, C. et al. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J. Virol. 83, 6817–6824 (2009).
Google Scholar
Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV–factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347 (2006). This paper reports adaptive immune responses to gene-therapy reagents as a major barrier to efficacy in clinical trials.
Google Scholar
Meadows, A. S., Pineda, R. J., Goodchild, L., Bobo, T. A. & Fu, H. Threshold for pre-existing antibody levels limiting transduction efficiency of systemic rAAV9 gene delivery: relevance for translation. Mol. Ther. Methods Clin. Dev. 13, 453–462 (2019).
Google Scholar
Li, A. et al. AAV–CRISPR gene editing is negated by pre-existing immunity to Cas9. Mol. Ther. 28, 1432–1441 (2020).
Google Scholar
Long, B. R. et al. The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy. Mol. Ther. Methods Clin. Dev. 13, 440–452 (2019).
Google Scholar
Mingozzi, F. & High, K. A. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu. Rev. Virol. 4, 511–534 (2017).
Google Scholar
Mingozzi, F. et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419–422 (2007).
Google Scholar
Wagner, D. L. et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat. Med. 25, 242–248 (2019).
Google Scholar
Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249–254 (2019).
Google Scholar
Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704–712 (2010).
Google Scholar
Shirley, J. L., de Jong, Y. P., Terhorst, C. & Herzog, R. W. Immune responses to viral gene therapy vectors. Mol. Ther. 28, 709–722 (2020).
Google Scholar
George, L. A. et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol. Ther. 28, 2073–2082 (2020).
Google Scholar
Chew, W. L. et al. A multifunctional AAV–CRISPR–Cas9 and its host response. Nat. Methods 13, 868–874 (2016).
Google Scholar
Rust, B. J. et al. Envelope-specific adaptive immunity following transplantation of hematopoietic stem cells modified with VSV-G lentivirus. Mol. Ther. Methods Clin. Dev. 19, 438–446 (2020).
Google Scholar
Milani, M. et al. Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy. EMBO Mol. Med. 9, 1558–1573 (2017).
Google Scholar
Calcedo, R. et al. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency. Proc. Natl Acad. Sci. USA 114, 1655–1659 (2017).
Google Scholar
Mendell, J. R. et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N. Engl. J. Med. 363, 1429–1437 (2010).
Google Scholar
Riddell, S. R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2, 216–223 (1996). This paper reports the first clinical trial in which gene-modified cells are cleared from the body owing to an adaptive immune response against the introduced transgene.
Google Scholar
Uchida, N. et al. Busulfan combined with immunosuppression allows efficient engraftment of gene-modified cells in a rhesus macaque model. Mol. Ther. 27, 1586–1596 (2019).
Google Scholar
Uchida, N. et al. Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic stem cell gene therapy model. Gene Ther. 21, 148–157 (2014).
Google Scholar
Bubnic, S. J., Nagy, A. & Keating, A. Donor hematopoietic cells from transgenic mice that express GFP are immunogenic in immunocompetent recipients. Hematology 10, 289–295 (2005).
Google Scholar
Rosenzweig, M. et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells. Blood 97, 1951–1959 (2001).
Google Scholar
Drysdale, C. M., Tisdale, J. F. & Uchida, N. Immunoresponse to gene-modified hematopoietic stem cells. Mol. Ther. Methods Clin. Dev. 16, 42–49 (2020).
Google Scholar
Uchida, N. et al. Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model. Mol. Ther. Methods Clin. Dev. 3, 16059 (2016).
Google Scholar
Kung, S. K. et al. Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. Mol. Ther. 8, 981–991 (2003).
Google Scholar
Manilay, J. O., Pearson, D. A., Sergio, J. J., Swenson, K. G. & Sykes, M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 66, 96–102 (1998).
Google Scholar
Styczynski, J. et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transpl. 55, 126–136 (2020).
Ogonek, J. et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front. Immunol. 7, 507 (2016).
Google Scholar
Mikhael, N. L. & Elsorady, M. Clinical significance of T cell receptor excision circle (TREC) quantitation after allogenic HSCT. Blood Res. 54, 274–281 (2019).
Google Scholar
Hakim, F. T. et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J. Clin. Invest. 115, 930–939 (2005).
Google Scholar
Bhatt, K. H. et al. Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance. Stem Cell. Res. Ther. 8, 57 (2017).
Google Scholar
Beagles, K. E., Peterson, L., Zhang, X., Morris, J. & Kiem, H. P. Cyclosporine inhibits the development of green fluorescent protein (GFP)-specific immune responses after transplantation of GFP-expressing hematopoietic repopulating cells in dogs. Hum. Gene Ther. 16, 725–733 (2005).
Google Scholar
Tarantal, A. F. et al. Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. Mol. Ther. 20, 1033–1045 (2012).
Google Scholar
Swart, J. F. et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat. Rev. Rheumatol. 13, 244–256 (2017).
Google Scholar
Sack, B. K., Herzog, R. W., Terhorst, C. & Markusic, D. M. Development of gene transfer for induction of antigen-specific tolerance. Mol. Ther. Methods Clin. Dev. 1, 14013 (2014).
Google Scholar
Coleman, M. A. et al. Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacy. Blood 121, 1049–1058 (2013).
Google Scholar
Furlan, R. A tolerizing mRNA vaccine against autoimmunity? Mol. Ther. 29, 896–897 (2021).
Google Scholar
Weischendorff, S. et al. Reduced plasma amino acid levels during allogeneic hematopoietic stem cell transplantation are associated with systemic inflammation and treatment-related complications. Biol. Blood Marrow Transpl. 25, 1432–1440 (2019).
Google Scholar
De La Serna, J. et al. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone Marrow Transplant. 51, 961–966 (2016).
Xun, C. Q., Thompson, J. S., Jennings, C. D., Brown, S. A. & Widmer, M. B. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83, 2360–2367 (1994).
Google Scholar
Squeri, G. et al. Targeting a pre-existing anti-transgene T cell response for effective gene therapy of MPS-I in the mouse model of the disease. Mol. Ther. 27, 1215–1227 (2019).
Google Scholar
Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010).
Google Scholar
Gouw, S. C. et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119, 2922–2934 (2012).
Google Scholar
Ponder, K. P. Immune response hinders therapy for lysosomal storage diseases. J. Clin. Invest. 118, 2686–2689 (2008).
Google Scholar
Lutzko, C. et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine α-l-iduronidase deficiency. Blood 93, 1895–1905 (1999).
Google Scholar
Gentner, B. et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N. Engl. J. Med. 385, 1929–1940 (2021).
Google Scholar
Yin, L. et al. CRISPR–Cas13a inhibits HIV-1 infection. Mol. Ther. Nucleic Acids 21, 147–155 (2020).
Google Scholar
Xu, L. et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240–1247 (2019).
Google Scholar
Burke, B. P. et al. Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol. Ther. Nucleic Acids 4, e236 (2015).
Google Scholar
Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to tnable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439–1453.e19 (2018).
Google Scholar
Voss, J. E. et al. Reprogramming the antigen specificity of B cells using genome-editing technologies. eLife 8, e42995 (2019).
Google Scholar
Greiner, V. et al. CRISPR-mediated editing of the B cell receptor in primary human B cells. iScience 12, 369–378 (2019).
Google Scholar
De Oliveira, S. N. et al. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum. Gene Ther. 24, 824–839 (2013).
Google Scholar
Vatakis, D. N. et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl Acad. Sci. USA 108, E1408–E1416 (2011).
Google Scholar
Irving, A. T., Ahn, M., Goh, G., Anderson, D. E. & Wang, L. F. Lessons from the host defences of bats, a unique viral reservoir. Nature 589, 363–370 (2021).
Google Scholar
Bai, T. et al. Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel. Nat. Med. 25, 1566–1575 (2019).
Google Scholar
Fares, I. et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 345, 1509–1512 (2014).
Google Scholar
Boitano, A. E. et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329, 1345–1348 (2010).
Google Scholar
Demirci, S., Leonard, A. & Tisdale, J. F. Hematopoietic stem cells from pluripotent stem cells: clinical potential, challenges, and future perspectives. Stem Cell Transl. Med. 9, 1549–1557 (2020).
Sandler, V. M. et al. Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature 511, 312–318 (2014).
Google Scholar
Riddell, J. et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell 157, 549–564 (2014). This paper is the first to demonstrate trans-differentiation of cells to HSCs.
Google Scholar
Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. Nat. Rev. Immunol. 18, 325–339 (2018).
Google Scholar
Robinson, J., Soormally, A. R., Hayhurst, J. D. & Marsh, S. G. E. The IPD-IMGT/HLA Database — new developments in reporting HLA variation. Hum. Immunol. 77, 233–237 (2016).
Google Scholar
Xu, H. et al. Targeted disruption of HLA genes via CRISPR–Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566–578.e7 (2019).
Google Scholar
Deuse, T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat. Biotechnol. 37, 252–258 (2019).
Google Scholar
Gornalusse, G. G. et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35, 765–772 (2017). This paper reports that hypoimmune cells allow for allogeneic transplantation without rejection or HLA matching.
Google Scholar
Deuse, T. et al. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice. Proc. Natl Acad. Sci. USA 118, e2022091118 (2021).
Google Scholar
Liu, X. et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat. Immunol. 12, 416–424 (2011).
Google Scholar
Madsen, L. et al. Mice lacking all conventional MHC class II genes. Proc. Natl Acad. Sci. USA 96, 10338–10343 (1999).
Google Scholar
Grusby, M. J. et al. Mice lacking major histocompatibility complex class I and class II molecules. Proc. Natl Acad. Sci. USA 90, 3913–3917 (1993).
Google Scholar
Burger, P., Hilarius-Stokman, P., de Korte, D., van den Berg, T. K. & van Bruggen, R. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 119, 5512–5521 (2012).
Google Scholar
Noyan, F. et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am. J. Transplant. 17, 917–930 (2017).
Google Scholar
Todo, S. et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology 64, 632–643 (2016).
Google Scholar
MacDonald, K. G. et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Invest. 126, 1413–1424 (2016).
Google Scholar
Akbarpour, M. et al. Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Sci. Transl. Med. 7, 289ra281 (2015).
Cunningham, E. C. et al. Gene therapy for tolerance: high-level expression of donor major histocompatibility complex in the liver overcomes naive and memory alloresponses to skin grafts. Transplantation 95, 70–77 (2013).
Google Scholar
Calne, R. Y. et al. Induction of immunological tolerance by porcine liver allografts. Nature 223, 472–476 (1969).
Google Scholar
Bernardo, M. E. & Aiuti, A. The role of conditioning in hematopoietic stem-cell gene therapy. Hum. Gene Ther. 27, 741–748 (2016).
Google Scholar
Chanut, F. J. A. et al. Conditioning regimens in long-term pre-clinical studies to support development of ex vivo gene therapy: review of nonproliferative and proliferative changes. Hum. Gene Ther. 32, 66–76 (2021).
Google Scholar
Agarwal, R. et al. First report of non-genotoxic conditioning with JSP191 (anti-CD117) and hematopoietic stem cell transplantation in a newly diagnosed patient with severe combined immune deficiency. Blood 136, 10–10 (2020).
Myburgh, R. et al. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34, 2688–2703 (2020).
Google Scholar
Chhabra, A. et al. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci. Transl. Med. 8, 351ra105 (2016).
Google Scholar
George, B. M. et al. Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance. Cell Stem Cell 25, 185–192.e3 (2019). This paper reports that antibody-mediated conditioning allows for HSCT between completely MHC-mismatched donor and recipient mice.
Google Scholar
Taya, Y. et al. Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation. Science 354, 1152–1155 (2016).
Google Scholar
Ochi, K., Morita, M., Wilkinson, A. C., Iwama, A. & Yamazaki, S. Non-conditioned bone marrow chimeric mouse generation using culture-based enrichment of hematopoietic stem and progenitor cells. Nat. Commun. 12, 3568 (2021).
Google Scholar
Shimoto, M., Sugiyama, T. & Nagasawa, T. Numerous niches for hematopoietic stem cells remain empty during homeostasis. Blood 129, 2124–2131 (2017). This work is the first demonstration of robust HSC engraftment without conditioning in immunocompetent mice.
Google Scholar
Rio, P. et al. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nat. Med. 25, 1396–1401 (2019).
Google Scholar
Wilkinson, A. C. et al. Cas9-AAV6 gene correction of β-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat. Commun. 12, 686 (2021).
Google Scholar
Ginn, S. L. et al. Limiting thymic precursor supply increases the risk of lymphoid malignancy in murine X-linked severe combined immunodeficiency. Mol. Ther. Nucleic Acids 6, 1–14 (2017).
Google Scholar
Pasi, K. J. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N. Engl. J. Med. 382, 29–40 (2020).
Google Scholar
Jacobson, S. G. et al. Improvement and decline in vision with gene therapy in childhood blindness. N. Engl. J. Med. 372, 1920–1926 (2015).
Google Scholar
Goldstein, J. M. et al. In situ modification of tissue stem and progenitor cell genomes. Cell Rep. 27, 1254–1264.e7 (2019).
Google Scholar
Humbert, O. et al. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy. Blood Adv. 2, 987–999 (2018).
Google Scholar
Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021). This work is the first clinical trial to use the CRISPR–Cas9 system in vivo.
Google Scholar
Krishnamurthy, S. et al. Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia. Nat. Commun. 10, 4906 (2019).
Google Scholar
Staahl, B. T. et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol. 35, 431–434 (2017).
Google Scholar
[No authors listed.] High-dose AAV gene therapy deaths. Nat. Biotechnol. 38, 910 (2020).
Sibbald, B. Death but one unintended consequence of gene-therapy trial. CMAJ 164, 1612 (2001).
Google Scholar
Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).
Google Scholar
Brown, B. D., Venneri, M. A., Zingale, A., Sergi Sergi, L. & Naldini, L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585–591 (2006).
Google Scholar
Dunleavy, K. With the pricing situation ‘untenable’ in Europe, Bluebird will wind down its operations in the ‘broken’ market. Fierce Pharma https://www.fiercepharma.com/pharma/situation-untenable-bluebird-will-wind-down-its-operations-broken-europe (2021).
Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nat. Rev. Genet. 22, 216–234 (2021).
Google Scholar
Cavazzana, M., Bushman, F. D., Miccio, A., Andre-Schmutz, I. & Six, E. Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat. Rev. Drug Discov. 18, 447–462 (2019).
Google Scholar
Aiuti, A., Roncarolo, M. G. & Naldini, L. Gene therapy for ADA–SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol. Med. 9, 737–740 (2017).
Google Scholar
Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).
Google Scholar
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Google Scholar
Yla-Herttuala, S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 20, 1831–1832 (2012).
Google Scholar
Porteus, M. H. & Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763 (2003).
Google Scholar
Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267 (1996).
Google Scholar
Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA–SCID: initial trial results after 4 years. Science 270, 475–480 (1995).
Google Scholar
Civin, C. I. et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol. 133, 157–165 (1984).
Google Scholar
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).
Google Scholar
Gyurkocza, B. & Sandmaier, B. M. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 124, 344–353 (2014).
Google Scholar
